BioCentury | Oct 27, 2020
Distillery Therapeutics

UCSF team develops trivalent binder of SARS-CoV-2 spike for COVID-19

...preclinical testing for COVID-19 include: a camelid neutralizing single-domain antibody from Abcore Inc.; a neutralizing protein from Avacta Group plc...
BioCentury | Aug 15, 2020
Management Tracks

Myriad chooses Diaz as new CEO; plus changes at Novocure, Werewolf, Jasper, Avacta, Tarsus and more

...He was CMO of NextCure Inc. (NASDAQ:NXTC). Jasper is developing hematopoietic cell transplant therapies.Immuno-oncology company Avacta Group plc...
...CMO. He was senior medical director at Johnson & Johnson (NYSE:JNJ). Robin Sawka Novocure Ltd. Werewolf Therapeutics Jasper Therapeutics Inc. Avacta Group plc Tarsus...
BioCentury | Apr 9, 2020
Product Development

April 8 COVID-19 roundup: National Academy of Sciences says COVID-19 could continue through summer; plus HHS, SAb-CSL, Vanda-UIC, Avacta-Cytiva and more

...that block CTSL from cleaving SARS-CoV-2 glycoproteins involved in viral fusion. Deal terms weren’t disclosed. Avacta Group plc...
...to develop and manufacture a point-of-care COVID-19 test using the former’s Affimer reagent technology. Avacta...
...Biopharma U.S. Department of Health and Human Services SAB Biotherapeutics Inc. CSL Ltd. Vanda Pharmaceuticals Inc. University of Illinois at Chicago Avacta Group plc GE...
BioCentury | Oct 11, 2019
Company News

Oct. 11 Company Quick Takes: FDA approves Lilly migraine drug; plus Clovis, Evotec-Celmatix, Avacta-ADC and Neumentum-J&J

...technology with ADC’s pyrrolobenzodiazepine (PBD)-based warhead and linker technologies. ADC will cover Avacta’s costs, and Avacta...
...#), PF-01367338 (Former compound #), AG-014699 (Former compound #), rucaparib (Generic) oral lasmiditan (LY573144, Oral COL-144, IY573144) Avacta Group plc Evotec...
BioCentury | Dec 14, 2018
Company News

LG Chem and Avacta partner to develop undisclosed targets

...rights to develop Affimer candidates against multiple undisclosed targets to treat inflammatory disorders and cancer. Avacta...
...Chem exercise an option to license additional targets. LG Chem will cover Avacta's R&D costs. Avacta...
...modifiers. Avacta Group plc (AIM:AVCT), Heslington, U.K. LG Chem Ltd. (KRX:051910), Seoul, South Korea Business: Cancer, Inflammation Shannon Lehnbeuter Avacta Group plc LG...
BioCentury | Jan 26, 2018
Company News

Avacta, OncoSec combine technologies

...Avacta’s Affimer protein platform, including its PD-L1 inhibitor AVA04, with OncoSec’s gene delivery technology ImmunoPulse. Avacta...
...not disclosed. Avacta Group plc (LSE:AVCT), Heslington, U.K. OncoSec Medical Inc. (NASDAQ:ONCS), San Diego, Calif. Business: Cancer Shannon Lehnbeuter Avacta Group plc OncoSec...
BioCentury | Nov 8, 2016
Company News

Avacta, Memorial Sloan Kettering deal

...Avacta and Memorial Sloan partnered to evaluate Avacta’s Affimer technology in CAR T cell applications. Affimers...
...are non-antibody scaffold proteins, which the company said may have advantages over antibody fragment technology. Avacta...
...their antitumor activity in preclinical testing. The partners will share ownership of the research results. Avacta Group plc...
BioCentury | Jul 25, 2016
Company News

Avacta, Glythera deal

...Avacta and Glythera partnered to develop targeted therapeutics using Avacta’s Affimer technology and Glythera’s PermaLink conjugation...
...pharmaceutical companies. Avacta declined to disclose financial terms, and Glythera did not respond to inquiries. Avacta Group plc...
BioCentury | Jul 21, 2016
Emerging Company Profile

Drugging the undruggable

...of Cambridge , University of Liverpool , University of Queensland , Wistar Institute Corporate partners: Avacta Group plc...
BioCentury | Jun 20, 2016
Company News

Avacta, Mologic deal

...from resulting marketed diagnostics. Avacta did not disclose financials. Mologic did not respond to inquiries. Avacta Group plc...
Items per page:
1 - 10 of 18
BioCentury | Oct 27, 2020
Distillery Therapeutics

UCSF team develops trivalent binder of SARS-CoV-2 spike for COVID-19

...preclinical testing for COVID-19 include: a camelid neutralizing single-domain antibody from Abcore Inc.; a neutralizing protein from Avacta Group plc...
BioCentury | Aug 15, 2020
Management Tracks

Myriad chooses Diaz as new CEO; plus changes at Novocure, Werewolf, Jasper, Avacta, Tarsus and more

...He was CMO of NextCure Inc. (NASDAQ:NXTC). Jasper is developing hematopoietic cell transplant therapies.Immuno-oncology company Avacta Group plc...
...CMO. He was senior medical director at Johnson & Johnson (NYSE:JNJ). Robin Sawka Novocure Ltd. Werewolf Therapeutics Jasper Therapeutics Inc. Avacta Group plc Tarsus...
BioCentury | Apr 9, 2020
Product Development

April 8 COVID-19 roundup: National Academy of Sciences says COVID-19 could continue through summer; plus HHS, SAb-CSL, Vanda-UIC, Avacta-Cytiva and more

...that block CTSL from cleaving SARS-CoV-2 glycoproteins involved in viral fusion. Deal terms weren’t disclosed. Avacta Group plc...
...to develop and manufacture a point-of-care COVID-19 test using the former’s Affimer reagent technology. Avacta...
...Biopharma U.S. Department of Health and Human Services SAB Biotherapeutics Inc. CSL Ltd. Vanda Pharmaceuticals Inc. University of Illinois at Chicago Avacta Group plc GE...
BioCentury | Oct 11, 2019
Company News

Oct. 11 Company Quick Takes: FDA approves Lilly migraine drug; plus Clovis, Evotec-Celmatix, Avacta-ADC and Neumentum-J&J

...technology with ADC’s pyrrolobenzodiazepine (PBD)-based warhead and linker technologies. ADC will cover Avacta’s costs, and Avacta...
...#), PF-01367338 (Former compound #), AG-014699 (Former compound #), rucaparib (Generic) oral lasmiditan (LY573144, Oral COL-144, IY573144) Avacta Group plc Evotec...
BioCentury | Dec 14, 2018
Company News

LG Chem and Avacta partner to develop undisclosed targets

...rights to develop Affimer candidates against multiple undisclosed targets to treat inflammatory disorders and cancer. Avacta...
...Chem exercise an option to license additional targets. LG Chem will cover Avacta's R&D costs. Avacta...
...modifiers. Avacta Group plc (AIM:AVCT), Heslington, U.K. LG Chem Ltd. (KRX:051910), Seoul, South Korea Business: Cancer, Inflammation Shannon Lehnbeuter Avacta Group plc LG...
BioCentury | Jan 26, 2018
Company News

Avacta, OncoSec combine technologies

...Avacta’s Affimer protein platform, including its PD-L1 inhibitor AVA04, with OncoSec’s gene delivery technology ImmunoPulse. Avacta...
...not disclosed. Avacta Group plc (LSE:AVCT), Heslington, U.K. OncoSec Medical Inc. (NASDAQ:ONCS), San Diego, Calif. Business: Cancer Shannon Lehnbeuter Avacta Group plc OncoSec...
BioCentury | Nov 8, 2016
Company News

Avacta, Memorial Sloan Kettering deal

...Avacta and Memorial Sloan partnered to evaluate Avacta’s Affimer technology in CAR T cell applications. Affimers...
...are non-antibody scaffold proteins, which the company said may have advantages over antibody fragment technology. Avacta...
...their antitumor activity in preclinical testing. The partners will share ownership of the research results. Avacta Group plc...
BioCentury | Jul 25, 2016
Company News

Avacta, Glythera deal

...Avacta and Glythera partnered to develop targeted therapeutics using Avacta’s Affimer technology and Glythera’s PermaLink conjugation...
...pharmaceutical companies. Avacta declined to disclose financial terms, and Glythera did not respond to inquiries. Avacta Group plc...
BioCentury | Jul 21, 2016
Emerging Company Profile

Drugging the undruggable

...of Cambridge , University of Liverpool , University of Queensland , Wistar Institute Corporate partners: Avacta Group plc...
BioCentury | Jun 20, 2016
Company News

Avacta, Mologic deal

...from resulting marketed diagnostics. Avacta did not disclose financials. Mologic did not respond to inquiries. Avacta Group plc...
Items per page:
1 - 10 of 18